340binformed.org

Your Free Source for 340B News and Commentary

  • About us
  • Advertise
  • Contact
  • 340B Health

GlaxoSmithKline Policy Threatens Asthma Care


 

Print Article

Feb. 16, 2022– Just days after President Biden spoke out in support of the 340B drug pricing program, drug giant GlaxoSmithKline (GSK) announced it will begin withholding 340B discounts starting in April for most safety-net hospitals. That action will bring the number of drug companies violating the 340B law to 14.

In 2021, GSK reported more than $45 billion in global sales, and it makes some of the top-selling drugs to treat asthma and chronic obstructive pulmonary disease (COPD). The company says its policy will not apply to community health centers and clinics that participate in 340B, but it will apply to hospitals that partner with community pharmacies to dispense drugs to their patients outside the hospital.

On Feb. 10, President Biden, speaking in Culpeper, Va., promoted his plans to curtail drug pricing in the U.S. In an event that also featured Rep. Abigail Spanberger (D-Va.), a strong 340B champion, the president said Spanberger “also has been relentless in making sure the law that’s been on the books that says pharmaceutical companies need to provide rural clinics and community health centers with discounts on prescription drugs is actually enforced. And we’re working together on that as well.”

That was the first time the president has spoken out on the 340B dispute. His administration has, however, been attempting to enforce the law, going to court to oppose several drug companies that are trying to block any enforcement actions taken against them. Three federal courts have issued decisions, with two courts ruling largely in favor of the government and one siding more with the drug companies involved. All three decisions have been appealed to higher courts, and the drugmakers have kept their policies in place while the appeals are pending.

Time for Penalties

In a statement, 340B Health President and Chief Executive Officer Maureen Testoni said, “In choosing to follow the lead of other drug companies that are violating federal law, GlaxoSmithKline will weaken the health care safety net and the patients who rely on it for care, including those with low incomes and those living in underserved rural communities.” She went on to note the GSK limits would harm safety-net hospitals caring for the 25 million Americans – including 5 million children – living with asthma. GSK said its policy will apply to Advair, Breo, Ventolin, Flovent, Trelegy, Anoro, Incruse, Arnuity, and Serevent.

The list of drug companies limiting 340B discounts now includes Eli Lilly, AstraZeneca, Sanofi, Novartis, Novo Nordisk, United Therapeutics, Boehringer Ingelheim, Merck, UCB, Amgen, AbbVie, Bristol Myers Squibb, Pfizer, and GSK. The government has sent enforcement letter to the first seven and is considering action on the others. The first six companies have also been referred to the Department of Health and Human Services Office of Inspector General for potential civil monetary fines of nearly $6,000 for each overcharge violation. Those could amount to hundreds of millions of dollars in fines for those companies. In her statement, Testoni said “the time has come” for those penalties to be imposed.

FOLLOW | SHARE | LIKE

  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

340B Health Twitter

340B HealthFollow

340B Health is the leading advocate & resource for hospitals that serve their communities by participating in the 340B drug pricing program. #Protect340B

340B Health
340BHealth340B Health@340BHealth·
12h

Safety-net hospitals use #340B savings to fund health services for patients who are uninsured. This enables these hospitals to meet their mission to the health care safety net. http://bit.ly/32J1uXk #Protect340B #MedTwitter

Reply on Twitter 1528856347873357826Retweet on Twitter 15288563478733578261Like on Twitter 15288563478733578261Twitter 1528856347873357826
340BHealth340B Health@340BHealth·
15h

.@metrohealthCLE's Dr. Sherrie Williams shares in @ThePlainDealer how #340B has been a vital resource for caring for patients during #COVID19. It frightens her to think what could happen if drug company restrictions on 340B pricing continue. https://bit.ly/3LEHwzY #Protect340B

Reply on Twitter 1528813986204069890Retweet on Twitter 1528813986204069890Like on Twitter 15288139862040698902Twitter 1528813986204069890
340BHealth340B Health@340BHealth·
19h

The effort to stop drug company restrictions on #340B discounts has broad support. A bipartisan group of 25 state attorneys general are urging federal appeals courts to decide in favor of @HHSGov enforcing the law. https://bit.ly/3yRgVwO #DrugPricing #Protect340B

Reply on Twitter 1528755777560797186Retweet on Twitter 1528755777560797186Like on Twitter 15287557775607971862Twitter 1528755777560797186
Load More...

RSS 340B Employed

  • Pharmacy 340B Technician FT/40HRS | CHRISTUS Health May 24, 2022
  • 340B Pharmacy Business Specialist | St. Luke's Health System May 24, 2022
  • 340B Program Director | Philadelphia FIGHT Community Health Centers May 11, 2022

Copyright © 2022 · 340B Health